Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15


Amplification of HER2 and TOP2A and deletion of TOP2A genes in a series of Taiwanese breast cancer.

Chen JR, Chien HP, Chen KS, Hwang CC, Chen HY, Yeh KY, Hsieh TY, Chang LC, Hsu YC, Lu RJ, Hua CC.

Medicine (Baltimore). 2017 Jan;96(2):e5582. doi: 10.1097/MD.0000000000005582.


TOP2A gene copy number change in breast cancer.

Engstrøm MJ, Ytterhus B, Vatten LJ, Opdahl S, Bofin AM.

J Clin Pathol. 2014 May;67(5):420-5. doi: 10.1136/jclinpath-2013-202052. Epub 2014 Jan 8.


Breast cancer adaptive resistance: HER2 and cancer stem cell repopulation in a heterogeneous tumor society.

Duru N, Candas D, Jiang G, Li JJ.

J Cancer Res Clin Oncol. 2014 Jan;140(1):1-14. doi: 10.1007/s00432-013-1494-1. Epub 2013 Aug 30. Review.


A common copy-number breakpoint of ERBB2 amplification in breast cancer colocalizes with a complex block of segmental duplications.

Marotta M, Chen X, Inoshita A, Stephens R, Budd GT, Crowe JP, Lyons J, Kondratova A, Tubbs R, Tanaka H.

Breast Cancer Res. 2012 Nov 26;14(6):R150. doi: 10.1186/bcr3362.


Prognostic significance of TOP2A gene dosage in HER-2-negative breast cancer.

Zaczek AJ, Markiewicz A, Seroczynska B, Skokowski J, Jaskiewicz J, Pienkowski T, Olszewski WP, Szade J, Rhone P, Welnicka-Jaskiewicz M, Jassem J.

Oncologist. 2012;17(10):1246-55. doi: 10.1634/theoncologist.2012-0023. Epub 2012 Aug 7.


TOP2A amplification in breast cancer in the absence of that of HER-2: myth or reality?

Lamy PJ, Jacot W.

Oncologist. 2012;17(12):e60-1. doi: 10.1634/theoncologist.2011-0430. Epub 2012 Jul 20. No abstract available.


TOPOIIalpha and HER-2/neu overexpression/amplification in Barrett's oesophagus, dysplasia and adenocarcinoma.

Rossi E, Villanacci V, Bassotti G, Donato F, Festa A, Cengia G, Grisanti S, Cestari R.

Histopathology. 2010 Jul;57(1):81-9. doi: 10.1111/j.1365-2559.2010.03580.x. Epub 2010 Jun 16.


Aberrations of ERBB2 and TOP2A genes in breast cancer.

Nielsen KV, Müller S, Møller S, Schønau A, Balslev E, Knoop AS, Ejlertsen B.

Mol Oncol. 2010 Apr;4(2):161-8. doi: 10.1016/j.molonc.2009.11.001. Epub 2009 Nov 18.


Genetic characterization of breast cancer and implications for clinical management.

Geyer FC, Lopez-Garcia MA, Lambros MB, Reis-Filho JS.

J Cell Mol Med. 2009 Oct;13(10):4090-103. doi: 10.1111/j.1582-4934.2009.00906.x. Epub 2009 Sep 14. Review.


Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status.

Tubbs R, Barlow WE, Budd GT, Swain E, Porter P, Gown A, Yeh IT, Sledge G, Shapiro C, Ingle J, Haskell C, Albain KS, Livingston R, Hayes DF.

J Clin Oncol. 2009 Aug 20;27(24):3881-6. doi: 10.1200/JCO.2008.20.1566. Epub 2009 Jul 20.


Topoisomerase II alpha status in renal medullary carcinoma: immuno-expression and gene copy alterations of a potential target of therapy.

Albadine R, Wang W, Brownlee NA, Toubaji A, Billis A, Argani P, Epstein JI, Garvin AJ, Cousi R, Schaeffer EM, Pavlovich C, Netto GJ.

J Urol. 2009 Aug;182(2):735-40. doi: 10.1016/j.juro.2009.03.078. Epub 2009 Jun 18.


Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance.

Lu J, Tan M, Huang WC, Li P, Guo H, Tseng LM, Su XH, Yang WT, Treekitkarnmongkol W, Andreeff M, Symmans F, Yu D.

Clin Cancer Res. 2009 Feb 15;15(4):1326-34. doi: 10.1158/1078-0432.CCR-08-0954.


Topoisomerase II alpha gene copy loss has adverse prognostic significance in ERBB2-amplified breast cancer: a retrospective study of paraffin-embedded tumor specimens and medical charts.

Usha L, Tabesh B, Morrison LE, Rao RD, Jacobson K, Zhu A, Basu S, Coon JS.

J Hematol Oncol. 2008 Aug 14;1:12. doi: 10.1186/1756-8722-1-12.


Prognostic role of topoisomerase-IIalpha in advanced ovarian cancer patients.

Ferrandina G, Petrillo M, Carbone A, Zannoni G, Martinelli E, Prisco M, Pignata S, Breda E, Savarese A, Scambia G.

Br J Cancer. 2008 Jun 17;98(12):1910-5. doi: 10.1038/sj.bjc.6604410. Epub 2008 May 27.


Altered expression pattern of topoisomerase IIalpha in ovarian tumor epithelial and stromal cells after platinum-based chemotherapy.

Chekerov R, Klaman I, Zafrakas M, Könsgen D, Mustea A, Petschke B, Lichtenegger W, Sehouli J, Dahl E.

Neoplasia. 2006 Jan;8(1):38-45.

Supplemental Content

Support Center